Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
about
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesPemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures ReviewThe Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and StagingMaintenance therapies for non-small cell lung cancerComplex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancerSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateA phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusPhase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerMaintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.Risks and benefits with bevacizumab: evidence and clinical implications.Pemetrexed in advanced non-small-cell lung cancer.Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Emerging role of pemetrexed in ovarian cancer.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLCAngiogenesis inhibitors in the treatment of non-small cell lung cancerFuture scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.Targeted therapies for non-small cell lung cancer: an evolving landscape.Surgical treatment of stage IV non-small cell lung cancer.Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer.Therapeutic antibodies against cancer.Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lungBevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma.Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyMaintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications.First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancerA phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.Update on the evidence regarding maintenance therapy.Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.
P2860
Q26745422-BA6B4399-1090-4291-97FC-EAF783D003B6Q26750670-5C407874-67CD-4F80-B3FA-FEF48D2BA7A8Q27001239-4E11A3F3-5CBC-4985-B7B7-4A6EF42C562BQ27021178-C057CC9F-7478-4E21-BA51-45022D6BBB4BQ30300843-A4111082-BF5E-4409-848E-CD2A5BFB67AEQ30356434-C54C9772-F856-4D57-B35E-143E6F602C24Q33392085-BE3961ED-B613-48E7-BF0B-00F56FC94DB5Q33400988-586E1C51-C5C3-49D9-95D0-C9529D17023FQ33401434-46A05FA3-A4CB-4413-A247-0DAD02F89311Q33404543-15797EC7-E0D6-43E1-8B5B-E77BA9FE87BCQ33417324-1665C88C-0659-4C00-A8D7-D7086AF00E49Q33428645-84F9F586-94E7-43AC-8696-64189CF6B26AQ33429242-130C6C67-7C2C-4B8B-B7A1-6E5652E0F104Q33437668-C3AE19A4-BB25-4095-A9E5-F34F8BE3252CQ33949406-DA3537CD-0C78-4061-BCD8-4E4EBF90162EQ34113895-76FAB5A9-AEE8-4281-9B96-42224F040498Q34427320-4F024359-7823-4ECE-B18A-6CC306324E2EQ34854658-C542C56E-82AE-4A06-8623-3860609D744DQ35015611-0A6C6FAB-A4EE-439E-9010-CEAA197BF16AQ35050210-33FB54C0-2B07-4665-B7DF-B623EAE94959Q35076198-8506537C-0781-46B0-B7FE-E1106160975FQ35583723-C32AD04D-ED3B-49A4-8D8D-73F34E1C7AACQ35628597-402894FB-D23C-42A2-AD11-DEABFEBD21E0Q35758398-5BA43357-E1FF-424E-8AD3-5E929B3F6CFAQ35789647-D0C3F3B6-830B-4BF5-8235-7EC84A0598EBQ35908498-037110F3-37D6-47F6-8F2A-3A779964A697Q36226281-F9B725C8-E88A-4D3B-8C15-ECED01AF57B9Q36649162-AAD71683-276D-4771-95F2-BBD5D017BB6AQ36741073-B28F0F3D-1031-4E9D-A65F-1FA9D13844CEQ36927640-AC45A08A-612F-47FF-9061-2B1D8327301FQ36996220-43AFAD79-44C0-4340-9061-37E86544E2A1Q37081896-49F822DD-D620-4DDE-8379-7D45C3DBCF8FQ37212223-26166784-A06A-4118-82B5-6B074DC13F39Q37347532-B1314A74-EB65-4811-86D8-4B5E99BA0C78Q37401072-726D2978-17EB-4891-B699-B592E2689445Q37419857-2EECD48D-AFBA-4BB5-B1D5-F7E94EEC0E3BQ37486262-423A3BA3-F065-4CD4-9A03-628893A7323BQ37558971-98FB7AAB-6DE6-4FAC-8F2C-74A1C5FBD1C1Q37575179-2C90C7F5-AA09-4864-839B-377E45098092Q37581974-07D3DAAE-2C47-478F-A9B6-AF2D3325F477
P2860
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@ast
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@en
type
label
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@ast
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@en
prefLabel
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@ast
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@en
P2093
P356
P1476
Phase II study of pemetrexed a ...... us non-small-cell lung cancer.
@en
P2093
Alfred Rademaker
Daniel T Milton
Eric M Hart
Jyoti D Patel
Matthew G Blum
Philip D Bonomi
Thomas A Hensing
P304
P356
10.1200/JCO.2008.20.8181
P407
P577
2009-05-11T00:00:00Z